UnitedHealth Group (NYSE:UNH) rose 7.45% last week, as health-care providers are starting to see increased membership, thanks to the Affordable Care Act. UnitedHealth competitor WellPoint, in particular, increased its full-year guidance this past week and expects more than 1 million new health plan members this year. UnitedHealth Group Inc. (NYSE:UNH) stock performance was -0.23% in last session and finished the day at $81.34. Traded volume was 11,530,121 million shares in the last session and the average volume of the stock remained 4.77 million shares. The beta of the stock remained 0.62. UnitedHealth Group Inc. (NYSE:UNH) insider ownership is 0.70%.

WellPoint Inc (NYSE:WLP) updated its FY14 earnings guidance on Friday. The company provided earnings per share guidance of ~$8.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.42, AnalystRatingsNetwork reports. WellPoint Inc (NYSE:WLP) rose 0.06 percent to $99.77 yesterday on volume of 7.62 million shares. The intra-day range of the stock was $99.65 to $102.56. WellPoint Inc (NYSE:WLP) has a market capitalization of $28.18 billion.

Equities research analysts at Sterne Agee began coverage on shares of Insulet Corp. (NASDAQ:PODD) in a research note issued to investors on Thursday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $61.00 price target on the stock. Insulet Corporation (NASDAQ:PODD)’s stock on Mar 21, 2014 reported a decrease of -0.68% to the closing price of $49.84. Its fifty two weeks range is $23.50 -$51.31. The total market capitalization recorded $2.72 billion. The overall volume in the last trading session was 475,368 million shares. In its share capital, Insulet Corporation (NASDAQ:PODD) has 54.46 million outstanding shares.

The Board of Directors (the “Board”) of Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) approved and the Company entered into a five-year employment agreement with Weibing Lu, the Company’s current Chairman of the Board and CEO (the “Employment Agreement”). On Friday, shares of Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) advanced 3.31% to close the day at $7.17. Company return on investment (ROI) is 6.30% and its monthly performance is recorded as 21.32%. Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) quarterly revenue growth is 96.44%.